CL2022003744A1 - Métodos para tratar la alergia usando anticuerpos anti-bet v 1 - Google Patents
Métodos para tratar la alergia usando anticuerpos anti-bet v 1Info
- Publication number
- CL2022003744A1 CL2022003744A1 CL2022003744A CL2022003744A CL2022003744A1 CL 2022003744 A1 CL2022003744 A1 CL 2022003744A1 CL 2022003744 A CL2022003744 A CL 2022003744A CL 2022003744 A CL2022003744 A CL 2022003744A CL 2022003744 A1 CL2022003744 A1 CL 2022003744A1
- Authority
- CL
- Chile
- Prior art keywords
- bet
- antibodies
- methods
- treat allergy
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063047126P | 2020-07-01 | 2020-07-01 | |
| US202063129253P | 2020-12-22 | 2020-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022003744A1 true CL2022003744A1 (es) | 2023-06-02 |
Family
ID=77168400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022003744A CL2022003744A1 (es) | 2020-07-01 | 2022-12-23 | Métodos para tratar la alergia usando anticuerpos anti-bet v 1 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11897945B2 (https=) |
| EP (1) | EP4175986A1 (https=) |
| JP (1) | JP2023531968A (https=) |
| KR (1) | KR20230030573A (https=) |
| CN (1) | CN115698059A (https=) |
| AU (1) | AU2021300129A1 (https=) |
| BR (1) | BR112022026279A2 (https=) |
| CA (1) | CA3177918A1 (https=) |
| CL (1) | CL2022003744A1 (https=) |
| IL (1) | IL299207A (https=) |
| MX (1) | MX2022015677A (https=) |
| WO (1) | WO2022006305A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL298034B2 (en) * | 2017-06-01 | 2024-05-01 | Regeneron Pharma | Antibodies against BET V 1 and methods of using them |
| CA3177918A1 (en) | 2020-07-01 | 2022-01-06 | Amanda ATANASIO | Methods of treating allergy using anti-bet v 1 antibodies |
| WO2024251358A1 (en) * | 2023-06-07 | 2024-12-12 | Mabylon Ag | Anti-allergen antibodies and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994010194A2 (de) | 1992-10-27 | 1994-05-11 | Biomay Produktions- Und Handelsgesellschaft M.B.H. | MOLEKÜLFRAGMENTE (PEPTIDE) DER HAUPTALLERGENE DER POLLEN VON BÄUMEN DER ORDNUNG $i(FAGALES) |
| WO1994014475A1 (en) | 1992-12-21 | 1994-07-07 | Tanox Biosystems, Inc. | ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT |
| EP0619323A1 (en) | 1993-04-09 | 1994-10-12 | Schering-Plough | Human monoclonal antibodies and processes and materials for making such antibodies |
| GB0002386D0 (en) | 2000-02-02 | 2000-03-22 | Novartis Nutrition Ag | Therapeutic composition |
| US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DK1219299T4 (da) | 2000-12-28 | 2011-02-14 | Biomay Ag | Allergivacciner og fremstilling deraf |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| ITMI20052517A1 (it) | 2005-12-29 | 2007-06-30 | Lofarma Spa | Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa |
| AT503297B1 (de) | 2006-05-18 | 2007-09-15 | Biomay Ag | Allergen-spezifische antikörper |
| TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| US10935554B2 (en) | 2013-08-23 | 2021-03-02 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT) |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| IL298034B2 (en) | 2017-06-01 | 2024-05-01 | Regeneron Pharma | Antibodies against BET V 1 and methods of using them |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| CA3177918A1 (en) | 2020-07-01 | 2022-01-06 | Amanda ATANASIO | Methods of treating allergy using anti-bet v 1 antibodies |
| US20250263471A1 (en) | 2024-01-30 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating allergy using anti-bet v 1 antibodies |
-
2021
- 2021-06-30 CA CA3177918A patent/CA3177918A1/en active Pending
- 2021-06-30 BR BR112022026279A patent/BR112022026279A2/pt unknown
- 2021-06-30 WO PCT/US2021/039945 patent/WO2022006305A1/en not_active Ceased
- 2021-06-30 JP JP2022579724A patent/JP2023531968A/ja active Pending
- 2021-06-30 AU AU2021300129A patent/AU2021300129A1/en active Pending
- 2021-06-30 MX MX2022015677A patent/MX2022015677A/es unknown
- 2021-06-30 US US17/364,299 patent/US11897945B2/en active Active
- 2021-06-30 EP EP21749400.4A patent/EP4175986A1/en active Pending
- 2021-06-30 KR KR1020227043651A patent/KR20230030573A/ko active Pending
- 2021-06-30 CN CN202180043390.9A patent/CN115698059A/zh active Pending
- 2021-06-30 IL IL299207A patent/IL299207A/en unknown
-
2022
- 2022-12-23 CL CL2022003744A patent/CL2022003744A1/es unknown
-
2023
- 2023-12-19 US US18/545,795 patent/US12583914B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023531968A (ja) | 2023-07-26 |
| US20240209074A1 (en) | 2024-06-27 |
| US12583914B2 (en) | 2026-03-24 |
| IL299207A (en) | 2023-02-01 |
| AU2021300129A1 (en) | 2022-12-08 |
| MX2022015677A (es) | 2023-02-22 |
| CA3177918A1 (en) | 2022-01-06 |
| EP4175986A1 (en) | 2023-05-10 |
| WO2022006305A1 (en) | 2022-01-06 |
| BR112022026279A2 (pt) | 2023-02-14 |
| US20220002394A1 (en) | 2022-01-06 |
| CN115698059A (zh) | 2023-02-03 |
| KR20230030573A (ko) | 2023-03-06 |
| US11897945B2 (en) | 2024-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022003744A1 (es) | Métodos para tratar la alergia usando anticuerpos anti-bet v 1 | |
| CL2024002250A1 (es) | Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria. | |
| CO2021007053A2 (es) | Métodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn | |
| EA201891284A1 (ru) | Композиции антител против cgrp и их применение | |
| EA033072B1 (ru) | Применение антител к семафорину 4d для лечения болезни хантингтона | |
| EA201692192A1 (ru) | СВЯЗЫВАЮЩЕЕСЯ С FcRn АНТИТЕЛО ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ | |
| AR074360A1 (es) | Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
| CR20170096A (es) | Tratamientos conjuntos con anticuerpos anti cd40 | |
| BR112021008060A2 (pt) | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento | |
| EA202191666A1 (ru) | Антитела к il-27 и их применение | |
| MX2022016039A (es) | Anticuerpos anti-cd2. | |
| PY2018606A (es) | Anticuerpo monoclonal que se une específicamente a GITR | |
| CL2021000146A1 (es) | Anticuerpos humanizados contra psma | |
| ZA202302084B (en) | Antibody that binds to vegf-a and ang2 and methods of use | |
| CL2021003335A1 (es) | Anticuerpo biespecífico para a-syn/igf1r y uso de este. | |
| MX2022012913A (es) | Anticuerpo anti-ox40 y usos del mismo. | |
| ECSP22056627A (es) | Anticuerpos contra la integrina alfa 11 beta 1 | |
| MX2024008933A (es) | Anticuerpos anti-musk para uso en el tratamiento de trastornos neuromusculares. | |
| BR112022009265A2 (pt) | Método de tratamento do câncer e método para aumentar, potencializar ou estimular uma resposta ou função imune | |
| MX2022004164A (es) | Anticuerpos anti-flt-1 para tratar displasia broncopulmonar. | |
| MX2024015304A (es) | Terapias combinadas con un anticuerpo antifactor xi/factor xia | |
| BR112022024020A2 (pt) | Composições compreendendo um anticorpo contra receptor de interleucina-6 para tratamento de artrite reumatoide e métodos de uso das mesmas | |
| BR112021019337A2 (pt) | Anticorpo anti-fgf23 | |
| WO2020033926A3 (en) | Antibodies that bind cd277 and uses thereof | |
| MX2021006396A (es) | Tratamiento topico de la diarrea, colitis o enterocolitis inducida por inhibidores de puntos de control inmunologico, utilizando anticuerpos y fragmentos de los mismos. |